Mitotic Stress Is an Integral Part of the Oncogene-Induced Senescence Program that Promotes Multinucleation and Cell Cycle Arrest

Cell Reports

Volumn 12, Issue 9, 2015, Pages 1483-1496

  Dikovskaya, Dina ^a   Cole, John J ^a   Mason, Susan M ^b   Nixon, Colin ^b   Karim, Saadia A ^b   McGarry, Lynn ^b   Clark, William ^b   Hewitt, Rachael N ^a   Sammons, Morgan A ^d   Zhu, Jiajun ^d   Athineos, Dimitris ^b   Leach, Joshua D G ^a   Marchesi, Francesco ^a   van Tuyn, John ^a   Tait, Stephen W ^a   Brock, Claire ^a   Morton, Jennifer P ^b   Wu, Hong ^c   Berger, Shelley L ^d   Blyth, Karen ^b   Adams, Peter D ^a   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MCL 1; PROTEIN P16; PROTEIN P21; MCL1 PROTEIN, HUMAN; RAS PROTEIN;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CHROMATIN; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS; MITOSIS INHIBITION; MITOSIS SPINDLE; ONCOGENE; ONCOGENE H RAS; ONCOGENIC INDUCED SENESCENCE; PRIORITY JOURNAL; SENESCENCE; UPREGULATION; CELL AGING; CELL CULTURE; CELL LINE; CYTOLOGY; GENETICS; GIANT CELL; METABOLISM; MUTATION;

CELL AGING; CELL LINE; CELLS, CULTURED; GIANT CELLS; HUMANS; MITOSIS; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; RAS PROTEINS;

EID: 84940794527     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.07.055     Document Type: Article

References (55)

1. Barradas M., Anderton E., Acosta J.C., Li S., Banito A., Rodriguez-Niedenführ M., Maertens G., Banck M., Zhou M.M., Walsh M.J., et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 2009, 23:1177-1182.
2. Berlingeri-Ramos A.C., Morales-Burgos A., Sánchez J.L., Nogales E.M. Spitz nevus in a Hispanic population: a clinicopathological study of 130 cases. Am. J. Dermatopathol. 2010, 32:267-275.
3. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dörken B., Jenuwein T., Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
4. Brito D.A., Rieder C.L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 2006, 16:1194-1200.
5. Burd C.E., Sorrentino J.A., Clark K.S., Darr D.B., Krishnamurthy J., Deal A.M., Bardeesy N., Castrillon D.H., Beach D.H., Sharpless N.E. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 2013, 152:340-351.
6. Caldwell M.E., DeNicola G.M., Martins C.P., Jacobetz M.A., Maitra A., Hruban R.H., Tuveson D.A. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2012, 31:1599-1608.
7. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8:729-740.
8. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
9. Cho R.J., Huang M., Campbell M.J., Dong H., Steinmetz L., Sapinoso L., Hampton G., Elledge S.J., Davis R.W., Lockhart D.J. Transcriptional regulation and function during the human cell cycle. Nat. Genet. 2001, 27:48-54.
10. Colin D.J., Hain K.O., Allan L.A., Clarke P.R. Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. Open Biol. 2015, 5:140156.
11. Collado M., Serrano M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 2010, 10:51-57.
12. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguría A., Zaballos A., Flores J.M., Barbacid M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
13. Demaria M., Ohtani N., Youssef S.A., Rodier F., Toussaint W., Mitchell J.R., Laberge R.M., Vijg J., Van Steeg H., Dollé M.E., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 2014, 31:722-733.
14. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
15. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
16. Ding Q., Huo L., Yang J.Y., Xia W., Wei Y., Liao Y., Chang C.J., Yang Y., Lai C.C., Lee D.F., et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008, 68:6109-6117.
17. Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315.
18. Fox D.T., Duronio R.J. Endoreplication and polyploidy: insights into development and disease. Development 2013, 140:3-12.
19. Fujiki H., Suganuma M., Yoshizawa S., Kanazawa H., Sugimura T., Manam S., Kahn S.M., Jiang W., Hoshina S., Weinstein I.B. Codon 61 mutations in the c-Harvey-ras gene in mouse skin tumors induced by 7,12-dimethylbenz[a]anthracene plus okadaic acid class tumor promoters. Mol. Carcinog. 1989, 2:184-187.
20. Ganem N.J., Pellman D. Linking abnormal mitosis to the acquisition of DNA damage. J. Cell Biol. 2012, 199:871-881.
21. Gray-Schopfer V.C., Cheong S.C., Chong H., Chow J., Moss T., Abdel-Malek Z.A., Marais R., Wynford-Thomas D., Bennett D.C. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br. J. Cancer 2006, 95:496-505.
22. Harley M.E., Allan L.A., Sanderson H.S., Clarke P.R. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010, 29:2407-2420.
23. Hayashi M.T., Karlseder J. DNA damage associated with mitosis and cytokinesis failure. Oncogene 2013, 32:4593-4601.
24. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
25. Holen K.D., Belani C.P., Wilding G., Ramalingam S., Volkman J.L., Ramanathan R.K., Vasist L.S., Bowen C.J., Hodge J.P., Dar M.M., Ho P.T. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother. Pharmacol. 2011, 67:447-454.
26. Hübner S., Eam J.E., Wagstaff K.M., Jans D.A. Quantitative analysis of localization and nuclear aggregate formation induced by GFP-lamin A mutant proteins in living HeLa cells. J. Cell. Biochem. 2006, 98:810-826.
27. Johmura Y., Shimada M., Misaki T., Naiki-Ito A., Miyoshi H., Motoyama N., Ohtani N., Hara E., Nakamura M., Morita A., et al. Necessary and sufficient role for a mitosis skip in senescence induction. Mol. Cell 2014, 55:73-84.
28. Jun J.I., Lau L.F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 2010, 12:676-685.
29. Krenning L., Feringa F.M., Shaltiel I.A., van den Berg J., Medema R.H. Transient activation of p53 in G2 phase is sufficient to induce senescence. Mol. Cell 2014, 55:59-72.
30. Kuilman T., Michaloglou C., Mooi W.J., Peeper D.S. The essence of senescence. Genes Dev. 2010, 24:2463-2479.
31. Leikam C., Hufnagel A., Schartl M., Meierjohann S. Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene 2008, 27:7070-7082.
32. Leikam C., Hufnagel A.L., Otto C., Murphy D.J., Mühling B., Kneitz S., Nanda I., Schmid M., Wagner T.U., Haferkamp S., et al. In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis. 2015, 6:e1711.
33. Leopold J.G., Richards D.B. Cellular blue naevi. J. Pathol. Bacteriol. 1967, 94:247-255.
34. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998, 12:3008-3019.
35. Liu Z., Li H., Derouet M., Filmus J., LaCasse E.C., Korneluk R.G., Kerbel R.S., Rosen K.V. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J. Biol. Chem. 2005, 280:37383-37392.
36. Mao Z., Ke Z., Gorbunova V., Seluanov A. Replicatively senescent cells are arrested in G1 and G2 phases. Aging (Albany, N.Y.) 2012, 4:431-435.
37. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
38. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010, 107:246-251.
39. Narita M., Nũnez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
40. Patino W.D., Hutchens K.A., Kapil J., Chiou Y., Gottlieb G.J. Eosinophilic cytoplasmic inclusion bodies in vesicular multinucleated melanocytes: a clue to the diagnosis of benign melanocytic lesions. Am. J. Dermatopathol. 2012, 34:424-427.
41. Quintanilla M., Brown K., Ramsden M., Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986, 322:78-80.
42. Rath O., Kozielski F. Kinesins and cancer. Nat. Rev. Cancer 2012, 12:527-539.
43. Reuter J.A., Khavari P.A. Use of conditionally active ras fusion proteins to study epidermal growth, differentiation, and neoplasia. Methods Enzymol. 2006, 407:691-702.
44. Rieder C.L., Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 2004, 7:637-651.
45. Salama R., Sadaie M., Hoare M., Narita M. Cellular senescence and its effector programs. Genes Dev. 2014, 28:99-114.
46. Savchenko IuI.u. [Endomitosis in pigmented neoplasms of human skin]. Tsitol. Genet. 1988, 22:20-24.
47. Smolle J., Kaddu S., Kerl H. Non-random spatial association of melanoma and naevi--a morphometric analysis. Melanoma Res. 1999, 9:407-412.
48. Stolz W., Schmoeckel C., Landthaler M., Braun-Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer 1989, 63:550-555.
49. Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., Deng Q., Yamout M., et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007, 128:295-308.
50. Takahashi A., Ohtani N., Yamakoshi K., Iida S., Tahara H., Nakayama K., Nakayama K.I., Ide T., Saya H., Hara E. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat. Cell Biol. 2006, 8:1291-1297.
51. Topham C.H., Taylor S.S. Mitosis and apoptosis: how is the balance set?. Curr. Opin. Cell Biol. 2013, 25:780-785.
52. Vergel M., Marin J.J., Estevez P., Carnero A. Cellular senescence as a target in cancer control. J. Aging Res. 2010, 2011:725365.
53. Walen K.H. Human diploid fibroblast cells in senescence; cycling through polyploidy to mitotic cells. In Vitro Cell. Dev. Biol. Anim. 2006, 42:216-224.
54. Young A.R., Narita M., Ferreira M., Kirschner K., Sadaie M., Darot J.F., Tavaré S., Arakawa S., Shimizu S., Watt F.M., Narita M. Autophagy mediates the mitotic senescence transition. Genes Dev. 2009, 23:798-803.
55. Zhu Y., Zhou Y., Shi J. Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle. Cell Cycle 2014, 13:1756-1764.